Effect of Empagliflozin on Inflammation for Coronary Patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stable coronary artery disease (CAD) and are scheduled to have a stent placed (PCI) for a new blockage in a natural heart artery.
- You have not taken any SGLT-2 inhibitor medication (like empagliflozin or similar drugs) in the past month.
- You are not currently on anti-inflammatory medications such as steroids, NSAIDs, or immune-suppressing drugs.
- You do not have an inflammatory condition like rheumatoid arthritis, an active infection, or active cancer.
- You have not had a heart attack or unstable chest pain in the last month.
- Your kidney function is good (estimated creatinine clearance above 30 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This study tests a pill called empagliflozin (commonly used for diabetes) to see if it can help people with chronic kidney disease who do not have diabetes. It looks at whether the drug can protect your blood vessels and slow down how quickly your kidneys get worse.
This trial tests whether giving empagliflozin (a diabetes medicine that may protect the heart) before or after emergency angioplasty for a first heart attack is better than a placebo. It aims to see if this medicine can improve recovery in South Asian patients.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
This trial tests whether a type of diabetes medicine called SGLT2 inhibitors can lower inflammation and stress markers in people with heart failure. It may help reduce damage to the heart and improve symptoms.
Hear when a new Inflamation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.